Sentence examples for modification by breast from inspiring English sources
A small number of variants were associated with risk in disease subgroup analyses and we observed no strong evidence of effect modification by breast cancer risk factors.
We evaluated potential effect modification by breast-feeding status and maternal age, because breast-feeding is a source of exposure to persistent organo-chlorine chemicals for infants, and older mothers are more likely to have higher serum concentrations.
There was also no evidence of effect modification by selected breast cancer risk factors or subgroup effects, including menopausal status.
We also investigated effect modification by established breast cancer risk factors that are associated with steroid hormone exposure.
We also examined effect modification by established breast cancer risk factors that are associated with steroid hormone exposure: body mass index (kg/m) among postmenopausal women (≥ 25 vs < 25 kg/m), use of hormone replacement therapy (current vs past vs never user of estrogen or estrogen + progestin) and age at menarche (≤ 12, vs > 12 years).
We examined the association between physical activity and volumetric mammographic density and the potential effect measure modification by the TC 10-year breast cancer risk in 38,913 Swedish women.
We also explored possible effect modification by the major breast cancer subtypes based on hormone receptor status: ER+/PR+ and ER-/PR- (Tables 6 and 7).
We therefore investigated the association between alcohol consumption and volumetric mammographic density and the potential effect measure modification by the Tyrer Cuzick breast cancer risk in 53 060 Swedish women.
No effect modification by family history of breast cancer was apparent for the relationship of BsmI to breast cancer (P interaction=0.93; data not shown).
Only results for effect modification by family history of breast cancer are reported since it is the only factor showing effect modification in the two studies.
A similar effect modification by PARP2 rs878156 was observed for breast cancer specific mortality after anthracycline-based chemotherapy.
